In a flash, after the American Cancer Society guidelines came out in favor of breast MRI for high-risk screening in late March, prominent radiology preauthorization company CareCore proclaimed it had been ahead of the times. The ACS release was a major coup for the technique.
In a flash, after the American Cancer Society guidelines came out in favor of breast MRI for high-risk screening in late March, prominent radiology preauthorization company CareCore proclaimed it had been ahead of the times. The ACS release was a major coup for the technique.
CareCore, which serves more than 30 million subscribers, issued a press release in April indicating that the recommendations were in line with evidence-based policies it had established more than two years ago.
The new ACS guidelines advise annual MRI screening along with mammography for women with a high lifetime risk of breast cancer. They could apply to 1 to 1.5 million women of screening age, and the ACS stamp of approval may impress insurance companies and lead to more uniform acceptance.
Along with the ACS guidelines, breast MRI got a boost earlier in the year when a large multicenter trial found MRI extremely useful in detecting or reliably ruling out mammographically occult cancer in the contralateral breast of women recently diagnosed with cancer in one breast (NEJM 2007;356[13]:1295-1313).
As breast MRI basked in positive publicity, computer-aided detection used in breast imaging came under intense attack with the release of a retrospective study that found CAD resulted in more false positives, recalls, and biopsies and produced lower overall accuracy compared with non-CAD environments (NEJM 2007;356;14:1399-1409).
FDA Clears Magnetic Resonance Spectroscopy Platform for Non-Invasive Assessment of Brain Chemistry
November 29th 2023BrainSpec Core reportedly offers enhanced sensitivity for low-grade gliomas and may facilitate the diagnosis of conditions including Alzheimer’s disease, multiple sclerosis, and epilepsy.
Study Says Contrast-Enhanced Mammography Offers Comparable Breast Cancer Detection to MRI
November 15th 2023In findings from an enriched cohort of asymptomatic patients with screening-detected abnormalities, researchers found that contrast-enhanced mammography (CEM) was superior to conventional mammography and offered equivalent detection of breast cancer in comparison to breast MRI and abbreviated breast MRI.
Adjunctive Brain Volume Quantification Tool for MRI Gets FDA Clearance
November 14th 2023Providing automated brain volume calculations based on MRI images, NeuroShield’s artificial intelligence (AI)-powered technology may help facilitate treatment for neurodegenerative conditions ranging from Alzheimer’s disease to epilepsy.